Abstract
CYP2C9, a drug-metabolizing enzyme, converts the angiotensin II receptor blocker losartan to its active form, which is responsible for its antihypertensive effect. We resequenced CYP2C9 in 724 Japanese individuals, including 39 hypertensive patients under treatment with losartan. Of two novel missense mutations dentified, the Arg132Gln variant showed a fivefold lower intrinsic clearance toward diclofenac when expressed in a baculovirus-insect cell system, while the Arg335Gln variant had no substantial effect. Several known missense variations were also found, and approximately 7% of the Japanese individuals (53 out of 724) carried one of the deleterious alleles (CYP2C9*3, *13, *14, *30, and Arg132Gln) as heterozygotes. After 3 months of losartan treatment, systolic blood pressure was not lowered in two patients with CYP2C9*1/*30, suggesting that they exhibited impaired in vivo CYP2C9 activity. CYP2C9*30 might be associated with a diminished response to the antihypertensive effects of losartan.
Similar content being viewed by others
Article PDF
References
Miners JO, Birkett DJ : Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998; 45: 525–538.
Evans WE, Relling MV : Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286: 487–491.
Lee CR, Goldstein JA, Pieper JA : Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 2002; 12: 251–263.
Kirchheiner J, Brockmoller J : Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther 2005; 77: 1–16.
Schwarz UI : Clinical relevance of genetic polymorphisms in the human CYP2C9 gene. Eur J Clin Invest 2003; 33 ( Suppl 2): 23–30.
Si D, Guo Y, Zhang Y, et al: Identification of a novel variant CYP2C9 allele in Chinese. Pharmacogenetics 2004; 14: 465–469.
Zhao F, Loke C, Rankin SC, et al: Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose. Clin Pharmacol Ther 2004; 76: 210–219.
DeLozier TC, Lee SC, Coulter SJ, et al: Functional characterization of novel allelic variants of CYP2C9 recently discovered in southeast Asians. J Pharmacol Exp Ther 2005; 315: 1085–1090.
Bae JW, Kim HK, Kim JH, et al: Allele and genotype frequencies of CYP2C9 in a Korean population. Br J Clin Pharmacol 2005; 60: 418–422.
Guo Y, Zhang Y, Wang Y, et al: Role of CYP2C9 and its variants (CYP2C9*3 and CYP2C9*13) in the metabolism of lornoxicam in humans. Drug Metab Dispos 2005; 33: 749–753.
Maekawa K, Fukushima-Uesaka H, Tohkin M, et al: Four novel defective alleles and comprehensive haplotype analysis of CYP2C9 in Japanese. Pharmacogenet Genomics 2006; 16: 497–514.
Dahlof B, Devereux RB, Kjeldsen SE, et al: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995–1003.
Baudin B : Angiotensin II receptor polymorphisms in hypertension. Pharmacogenomic considerations. Pharmacogenomics 2002; 3: 65–73.
Lo MW, Goldberg MR, McCrea JB, et al: Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin Pharmacol Ther 1995; 58: 641–649.
Stearns RA, Chakravarty PK, Chen R, Chiu SH : Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members. Drug Metab Dispos 1995; 23: 207–215.
Yasar U, Tybring G, Hidestrand M, et al: Role of CYP2C9 polymorphism in losartan oxidation. Drug Metab Dispos 2001; 29: 1051–1056.
Yasar U, Forslund-Bergengren C, Tybring G, et al: Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clin Pharmacol Ther 2002; 71: 89–98.
Yasar U, Dahl ML, Christensen M, Eliasson E : Intra-individual variability in urinary losartan oxidation ratio, an in vivo marker of CYP2C9 activity. Br J Clin Pharmacol 2002; 54: 183–185.
Babaoglu MO, Yasar U, Sandberg M, et al: CYP2C9 genetic variants and losartan oxidation in a Turkish population. Eur J Clin Pharmacol 2004; 60: 337–342.
Sekino K, Kubota T, Okada Y, et al: Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects. Eur J Clin Pharmacol 2003; 59: 589–592.
Matayoshi T, Kamide K, Takiuchi S, et al: The thiazidesensitive Na+-Cl− cotransporter gene, C1784T, and adrenergic receptor-β3 gene, T727C, may be gene polymorphisms susceptible to the antihypertensive effect of thiazide diuretics. Hypertens Res 2004; 27: 821–833.
Kimura R, Miyashita K, Kokubo Y, et al: Genotypes of vitamin K epoxide reductase, γ-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients. Thromb Res 2007; 120: 181–186.
Kamide K, Tanaka C, Takiuchi S, et al: Six missense mutations of the epithelial sodium channel β and γ subunits in Japanese hypertensives. Hypertens Res 2004; 27: 333–338.
Kamide K, Takiuchi S, Tanaka C, et al: Three novel missense mutations of WNK4, a kinase mutated in inherited hypertension, in Japanese hypertensives: implication of clinical phenotypes. Am J Hypertens 2004; 17: 446–449.
Kamide K, Yang J, Kokubo Y, et al: A novel missense mutation, F826Y, in the mineralocorticoid receptor gene in Japanese hypertensives: its implications for clinical phenotypes. Hypertens Res 2005; 28: 703–709.
Kamide K, Kokubo Y, Hanada H, et al: Genetic variations of HSD11B2 in hypertensive patients and in the general population, six rare missense/frameshift mutations. Hypertens Res 2006; 29: 243–252.
Kimura R, Kokubo Y, Miyashita K, et al: Polymorphisms in vitamin K–dependent γ-carboxylation–related genes influence interindividual variability in plasma protein C and protein S activities in the general population. Int J Hematol 2006; 84: 387–397.
Yin T, Hanada H, Miyashita K, et al: No association between vitamin K epoxide reductase complex subunit 1– like 1 (VKORC1L1) and the variability of warfarin dose requirement in a Japanese patient population. Thromb Res 2008; 122: 179–184.
Banno M, Hanada H, Kamide K, et al: Association of genetic polymorphisms of endothelin-converting enzyme-1 gene with hypertension in a Japanese population and rare missense mutation in preproendothelin-1 in Japanese hypertensives. Hypertens Res 2007; 30: 513–520.
Kokame K, Matsumoto M, Soejima K, et al: Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor–cleaving protease activity. Proc Natl Acad Sci U S A 2002; 99: 11902–11907.
Williams PA, Cosme J, Ward A, et al: Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature 2003; 424: 464–468.
Omura T, Sato R : The carbon monoxide–binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 1964; 239: 2370–2378.
Phillips AH, Langdon RG : Hepatic triphosphopyridine nucleotide-cytochrome c reductase: isolation, characterization, and kinetic studies. J Biol Chem 1962; 237: 2652–2660.
Yamazaki H, Nakajima M, Nakamura M, et al: Enhancement of cytochrome P-450 3A4 catalytic activities by cytochrome b5 in bacterial membranes. Drug Metab Dispos 1999; 27: 999–1004.
Shintani M, Ieiri I, Inoue K, et al: Genetic polymorphisms and functional characterization of the 5′ -flanking region of the human CYP2C9 gene: in vitro and in vivo studies. Clin Pharmacol Ther 2001; 70: 175–182.
Nasu K, Kubota T, Ishizaki T : Genetic analysis of CYP2C9 polymorphism in a Japanese population. Pharmacogenetics 1997; 7: 405–409.
Yin T, Miyata T : Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1-rationale and perspectives. Thromb Res 2007; 120: 1–10.
Bridges A, Gruenke L, Chang YT, et al: Identification of the binding site on cytochrome P450 2B4 for cytochrome b5 and cytochrome P450 reductase. J Biol Chem 1998; 273: 17036–17049.
Crespi CL, Miller VP : The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH: cytochrome P450 oxidoreductase. Pharmacogenetics 1997; 7: 203–210.
Blaisdell J, Jorge-Nebert LF, Coulter S, et al: Discovery of new potentially defective alleles of human CYP2C9. Pharmacogenetics 2004; 14: 527–537.
Tai G, Farin F, Rieder MJ, et al: In-vitro and in-vivo effects of the CYP2C9*11 polymorphism on warfarin metabolism and dose. Pharmacogenet Genomics 2005; 15: 475–481.
Lee CR, Pieper JA, Hinderliter AL, Blaisdell JA, Goldstein JA : Losartan and E3174 pharmacokinetics in cytochrome P450 2C9*1/*1, *1/*2, and *1/*3 individuals. Pharmacotherapy 2003; 23: 720–725.
Lajer M, Tarnow L, Andersen S, Parving HH : CYP2C9 variant modifies blood pressure–lowering response to losartan in Type 1 diabetic patients with nephropathy. Diabet Med 2007; 24: 323–325.
Afzelius L, Zamora I, Ridderstrom M, Andersson TB, Karlen A, Masimirembwa CM : Competitive CYP2C9 inhibitors: enzyme inhibition studies, protein homology modeling, and three-dimensional quantitative structureactivity relationship analysis. Mol Pharmacol 2001; 59: 909–919.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yin, T., Maekawa, K., Kamide, K. et al. Genetic Variations of CYP2C9 in 724 Japanese Individuals and Their Impact on the Antihypertensive Effects of Losartan. Hypertens Res 31, 1549–1557 (2008). https://doi.org/10.1291/hypres.31.1549
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1291/hypres.31.1549
Keywords
This article is cited by
-
Distributive characteristics of the CYP2C9 and AGTR1 genetic polymorphisms in Han Chinese hypertensive patients: a retrospective study
BMC Cardiovascular Disorders (2021)
-
Effects of polymorphic variation on the thermostability of heterogenous populations of CYP3A4 and CYP2C9 enzymes in solution
Scientific Reports (2018)
-
An update on the pharmacogenetics of treating hypertension
Journal of Human Hypertension (2015)
-
CYP2C9 polymorphism analysis in Han Chinese populations: building the largest allele frequency database
The Pharmacogenomics Journal (2014)
-
In vitro functional characterization of 37 CYP2C9 allelic isoforms found in Chinese Han population
Acta Pharmacologica Sinica (2013)